AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01689753 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trisodium citrate
Study NCT04231240 — intervention group
Intervention type: DEVICE
Intervention: Measure of ACT with IStat
Description: Measure of ACT with a point of care device named IStat
Study NCT02857036 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: rhythmic parameter recording
Description: the following rhythmic parameters are recording during 48 hours: temperature, heart rate and actimetry
Study NCT02857036 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: psychiatric assessment
Description: different psychometric scales are filled in: Montgomery and Asberg depression rating scale (MADRS), Quick inventory depression scale (QIDS-C16) and Beck depression inventory (BDI)
Study NCT01500993 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Capecitabine standard therapy (i.e. 2,500 mg/sqm) x 5 cycles plus 1 cycle of capecitabine based chemoradiotherapy (1.650 mg/sqm)
Study NCT01500993 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-FU
Description: 4 cycles of bolus 5-FU (500 mg/sqm) and 1 cycle of 5-FU based chemoradiotherapy (either 1,000 mg/sqm/day infusional 5-Fu days 1-5 and 29-33 or 225 mg/sqm/day infusional 5-Fu throughout the time of chemoradiotherapy)
Study NCT03229486 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sugammadex Injection [Bridion]
Description: Return to T2 point (two contractions) on TOF device is replied by iv 2 mg/kg sugammadex administration, contained in a blinded syringe.
Study NCT03229486 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Neostigmine+Glycopyrronium
Description: Return to T2 point (two contractions) on TOF device is replied by iv 0.06 mg/kg neostigmine and 0.005 mg/kg glycopyrrolate administration, contained in a blinded syringe.
Study NCT03547245 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: eOD-GT8 60mer + AS01B/ DPBS sucrose/IM
Description: 20 μg
Study NCT03547245 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: eOD-GT8 60mer + AS01B/ DPBS sucrose/IM
Description: 100 μg
Study NCT03547245 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: DPBS Sucrose
Description: Placebo
Study NCT03547245 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: DPBS Sucrose
Description: Placebo
Study NCT02265666 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIL 284 BS Tablet FF
Study NCT02265666 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BIIL 284 BS tablet C
Study NCT02265666 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: standard breakfast
Study NCT02265666 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: standard breakfast
Study NCT02296892 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remimazolam
Description: For induction and maintenance of sedation
Study NCT02296892 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Inactive control arm
Study NCT02296892 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam
Description: For induction and maintenance of sedation
Study NCT02745639 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: VMAT-SIB
Description: Radiation dose prescribed to PTV2 was 45 Gy (1.8 Gy/fraction), five sessions weekly in 25 daily fractions. A simultaneous boost was delivered on PTV1 with a total dose of 57.5 Gy (2.3 Gy/fraction). Dose-volume histograms (DVHs) were calculated for the PTV1, PTV2 and OARs. Patients were treated only if the relative variations of the bone markers between the images were within 3 mm along the three spatial directions. Planning and delivery processes underwent to systematic independent-check procedures.
Study NCT02745639 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XELOX
Description: The prescribed concurrent chemotherapy consisted of oxaliplatin infusion 130 mg/m2 on days 1, 17, 35 and capecitabine 1650 mg/m2 daily (825 mg/m² twice daily, 5 days/week) over all the treatment. An adequate blood count was necessary to start each chemotherapy infusion. Adjuvant chemotherapy was recommended on patients with high risk factors at pathological examination and decision was left to medical oncologists discretion.
Study NCT02653209 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitagliptin - DPP4i
Description: DPP4 inhibitor 100mg supplied as over-encapsulated hard capsule shell to be taken orally, once a day for 16 weeks in addition to existing prescribed oral diabetes therapy.
Study NCT02653209 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canagliflozin - SGLT2i
Description: SGLT2 inhibitor 100mg supplied as over-encapsulated hard capsule shell to be taken orally, once a day for 16 weeks in addition to existing prescribed oral diabetes therapy.
Study NCT02653209 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone - TZD
Description: Thiazolidinedione 30mg supplied as over-encapsulated hard capsule shell to be taken orally, once a day for 16 weeks in addition to existing prescribed oral diabetes therapy.
Study NCT02874599 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dental restoration
Description: Damaged teeth will be restored
Study NCT03465943 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ringer
Description: 1L of Ringer's solution as a preload in one group.
Study NCT03465943 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Voluven
Description: 500 ml of voluven will be given in combination with 500 ml Ringer's solution as a preload in the other group.
Study NCT03448536 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naproxen Sodium, (Aleve, BAY117031)
Description: 220 mg \*2 tablets, orally, single dose
Study NCT03448536 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen (Tylenol Extra Strength)
Description: 500 mg \*2 caplets, orally, single dose
Study NCT01403649 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Private/public collaboration to increase flu vaccination
Description: Intervention practices will develop office-based interventions including methods to identify high-risk patients within their practices and methods of maximizing the immunization of these children within the practice, use of patient reminders, after-hours influenza clinics, walk-in provision of influenza vaccine and increased focus on education regarding the need for immunization. The practices will also collaborate with their county public health departments and visiting nursing associations to develop private-public collaborative interventions that may include large clinics for school-aged children for multiple practices and tracking of influenza supplies and redistribution of influenza vaccine between practices when supplies are delayed or inadequate.
Study NCT01403649 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Usual care
Description: This group will continue administering influenza vaccine to their patients in their practice as they normally do.
Study NCT01493037 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: PICSO (Pressure-controlled Intermittent Coronary Occlusion
Description: The PICSO catheter has a balloon which is placed in the coronary sinus via the femoral vein. The balloon is inflated and deflated at intervals calculated by an algorithm and adjusted according to the patient's own coronary sinus pressure plateau.
Study NCT05144399 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Accelerated antibiotic treatment
Description: E. faecalis uncomplicated: 4 weeks.~E. faecalis complicated: 4 weeks.~S. aureus uncomplicated: 2 weeks.~S. aureus complicated: 4 weeks.~Streptococci spp. NVE: 2 weeks.~Streptococci spp. PVE or abscess: 3 weeks.~Subsequent to cardiac surgery with a negative valve culture (organism NOT grown in laboratory from valve): Minimum 1 week after surgery regardless of previous antibiotic treatment received.~Subsequent to cardiac surgery with a positive valve culture (organism grown in laboratory from valve): treatment will continue with the start date of antibiotics changed to the date of surgery.~Complicated IE defined as patients with abscess, embolic event, surgically treated IE, and/or PVE.~NVE: native valve endocarditis, PVE: prosthetic valve endocarditis.
Study NCT05144399 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Standard treatment length
Description: E. faecalis uncomplicated: 6 weeks.~E. faecalis complicated: 6 weeks.~S. aureus uncomplicated: 4 weeks.~S. aureus complicated: 6 weeks.~Streptococci spp. NVE: 4 weeks.~Streptococci spp. PVE or abscess: 6 weeks.~Subsequent to cardiac surgery with a negative valve culture (organism NOT grown in laboratory from valve): Minimum 2 weeks after surgery regardless of previous antibiotic treatment received.~Subsequent to cardiac surgery with a positive valve culture (organism grown in laboratory from valve): treatment will continue with the start date of antibiotics changed to the date of surgery.~Complicated IE defined as patients with abscess, embolic event, surgically treated IE, and/or PVE.~NVE: native valve endocarditis, PVE: prosthetic valve endocarditis.
Study NCT01582698 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: FSME-IMMUN 0.5 ml
Description: Solution/suspension for injection (intramuscular injection into the deltoid muscle of the right or left upper arm). Dosage frequency of booster vaccination: dependent on serum TBE antibodies.
Study NCT01335945 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Cryoablation
Description: All subjects will receive cryoablation of the celiac plexus with Galil Medical cryoablation systems and needles under imaging guidance.
Study NCT04016116 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab IV every 3 weeks
Study NCT04016116 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Description: Ruxolitinib po days 1-21
Study NCT02781649 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zepatier
Description: Fixed dose Grazoprevir 100 mg/Elbasvir 50 mg by mouth daily for 12 weeks
Study NCT02781649 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: Ribavirin 1200 mg/d (> 75 kg) or 1000 mg/d (\< 75 kg) by mouth daily in two divided doses
Study NCT02781649 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sofosbuvir
Description: Sofosbuvir 400 mg daily
Study NCT02568670 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: clinical signs
Description: to remove the peripheral venous catheter according clinical signs
Study NCT01722747 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tobacco Free Teachers, Tobacco Free Society (TFT/TFS)
Description: A 7-month intervention was conducted over one academic year \& included the following core components: 1. A Lead Teacher (LT) in each school was appointed and trained to facilitate the program on-site; 2. A tobacco policy was implemented; 3. Study health educators and LTs conducted group discussions with teachers addressing 6 intervention themes; 4. Materials; 5. Support for tobacco use cessation. Schools randomized to delayed intervention control condition did not receive any intervention until after final data collection, when they were given a 3-month shortened intervention.
Study NCT02761447 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treatment Traditional and Imaginary Motor Program
Description: Amputees patients also conservative protocol will undergo physiotherapy techniques work Imaginary Motor. The first video will include two sequences of a harmonic gear that will allow the patient to examine, with the physiotherapist, the characteristics of the different body segments involved in locomotion and place the member in space. The second video include an analysis in five phases: a) relaxation of Benson, b) phase external imagination where cycles of normal running on a video provided by the physiotherapist, c) phase internal imagination where the patient will identify the problem discussed compared with the normal course presented in the video, d) recreation of images in the first person made an e normalized locomotion) closing his eyes, prompted the patient to mentally recreate sequences normal gait and analyzed and subsequently verbalize differences of these with respect to their own way of getting around.
Study NCT02761447 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment Traditional and Mirror Therapy
Description: Amputees patients also conservative protocol will undergo physiotherapy techniques mirror therapy work. The protocol will consist of mirror therapy sessions three days a week (25-30 minutes) for a month, where participants will move the intact limb looking in the mirror and imagining the movement of the limb with phantom sensation.
Study NCT02762903 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TSA with tenotomy technique
Description: Standard procedure: Utilization of tenotomy for mobilization of subscapularis during total shoulder arthroplasty (TSA). The subscapularis tendon is incised close to its attachment on the humerus. The Tendon is repaired with sutures.
Study NCT02762903 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TSA with lesser tuberosity osteotomy technique
Description: Standard procedure: Utilization of the osteotomy to mobilize the subscapularis during TSA. A small fleck of bone is removed from humerus, the subscapularis tendon is still attached. The fleck of bone is reattached with sutures.
Study NCT02762903 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Shoulder prosthesis
Description: Standard procedure: Total shoulder arthroplasty replaces both components of the ball and socket joint with a metal device.
Study NCT02906722 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous colimycin
Description: administration once, twice or 3 times per day according to renal function
Study NCT02906722 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous placebo
Description: administration once, twice or 3 times per day according to renal function
Study NCT02906722 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nebulized colimycin
Description: Nebulization is performed with a vibrating plate nebulizer (Aeroneb® Solo) every 8h
Study NCT02906722 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nebulized placebo
Description: Nebulization is performed with a vibrating plate nebulizer (Aeroneb® Solo) every 8h
Study NCT01568385 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-438
Study NCT01292304 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tolvaptan
Description: Oral administration once daily Dosage will range from 15 mg to 30 mg
Study NCT01957540 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ticagrelor
Study NCT01957540 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Study NCT01957540 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prasugrel
Study NCT01957540 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prasugrel
Study NCT02043743 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Biological: Stem Cells
Description: Biological: Stem Cells 60 ml of bone marrow will aspirated and used for stem cells isolation. Then stem cells will cultured using autologous serum, characterized and prepared using GMP rules and finally 3-5 million MSCs injected into ovarian tissue.
Study NCT05131802 — intervention group
Intervention type: DEVICE
Intervention: upper GIT endescopy
Description: Gastric mucosa alterations as erythema, bile existence in the stomach, gastric folds thickening, erosions, and petechiae were also recorded (Olympus single-channel CLK-4). Multiple biopsies were taken from gastric mucosa for histopathological study. Via Triple Lumen ERCP Cannula, 5 mL of gastric fluid was aspirated through the suction channel of the endoscope and collected in a sterile trap placed in the suction line, to be sent for analysis. Quantitative determination of gastric aspirate total bilirubin level was performed (Gen.3® kit and Cobas 8000 analyzer). The pH monitoring of gastric aspirate was performed during the gastroscopy just after collection with a glass electrode pH meter (Adwa®).
Study NCT02441868 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Shortness of breath recognition and treatment
Description: Hospice registered nurses will train family caregivers about how to recognize patient shortness of breath. This training will employ a guided learning tool the Respiratory Distress Observation Scale-Family. Training will be done with a DVD and return demonstration of the skills using the patient. In addition, the family will be taught the bundle of evidence-based interventions to treat shortness of breath.
Study NCT04539223 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Evolocumab
Description: Autoinjector 1-mL deliverable volume of 140 mg/mL
Study NCT04147858 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NYX-2925
Description: NYX-2925 administered orally
Study NCT04147858 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo administered orally
Study NCT02623660 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ODIN1
Description: Shortly after surgery, electrodes will be applied to the lower extremity in such a way that the current will flow from the ankle through the knee replacement and pass through the thigh. The frequency of the treatments will vary over the period of time from post-op recovery to end of rehab.~All treatments are applying current that consists of different combinations of intensities within the micro to nano ampere ranges.
Study NCT02623660 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care
Description: Anti-thrombotic medication. Elevation and ice. Pain medications as needed. Dressings changes. Topical antibiotics. Progressive physical therapy.
Study NCT02623660 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard Care
Description: Anti-thrombotic medication. Elevation and ice. Pain medications as needed. Dressings changes. Topical antibiotics. Progressive physical therapy.
Study NCT02623660 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Diagnostic Device Testing
Description: Diagnostic interventions include: the Perometer which scans the lower extremity and determines its volume to a high degree of accuracy; the Impedimed Bioimpedance Spectroscopy (BIS) device that measures intra and intercellular fluid movement; the Microfet muscle force testing device that provides a digital output of the number of pounds exerted by the quadriceps upon extension; the Acumar digital digital Inclinometer that accurately measures the ROM of the knee; and the K.I.S.S. wound measuring system to measure rate of incision healing.
Study NCT02623660 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Diagnostic Device Testing
Description: Diagnostic interventions include: the Perometer which scans the lower extremity and determines its volume to a high degree of accuracy; the Impedimed Bioimpedance Spectroscopy (BIS) device that measures intra and intercellular fluid movement; the Microfet muscle force testing device that provides a digital output of the number of pounds exerted by the quadriceps upon extension; the Acumar digital digital Inclinometer that accurately measures the ROM of the knee; and the K.I.S.S. wound measuring system to measure rate of incision healing.
Study NCT00797888 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: telephonic
Description: Between 4-8 phone calls each year for health behavior counseling to improve HbA1c
Study NCT00797888 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: telephonic
Description: Between 4-8 phone calls each year for health behavior counseling to improve HbA1c
Study NCT00632502 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Navarixin
Description: Navarixin 30 mg capsule to be taken by mouth once daily in the morning for 4 weeks.
Study NCT00632502 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsule to match navarixin to be taken by mouth once daily in the morning for 4 weeks.
Study NCT00632502 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rescue medication
Description: Participant choice of short-acting beta-2 agonist (salbutamol/albuterol), anticholinergic, or combination medication as needed for asthma symptoms
Study NCT00632502 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Rescue medication
Description: Participant choice of short-acting beta-2 agonist (salbutamol/albuterol), anticholinergic, or combination medication as needed for asthma symptoms
Study NCT04601636 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active Prewarming
Description: Active prewarming with Flex Warming Gown (Bair Paws, 3M) for at least 30 minutes before induction of anesthesia, with active warming intraoperatively with Bair Hugger (3M)
Study NCT04601636 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standard Care
Description: Standard care with a passive prewarming (warm cotton blankets) before induction of anesthesia, with active warming intraoperatively with (Bair Hugger, 3M)
Study NCT02675049 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% saline
Description: 0.9% saline intranasally 45 min before surgery using a computer-generated random number table.
Study NCT02675049 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexmedetomidine 1µg.kg-1
Description: dexmedetomidine 1µg.kg-1 intranasally 45 min before surgery using a computer-generated random number table.
Study NCT02675049 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexmedetomidine 1.5µg.kg-1
Description: Dexmedetomidine 1.5µg.kg-1 intranasally 45 min before surgery using a computer-generated random number table.